Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

被引：0
|
作者：
Jun Gong
Shant Thomassian
Sungjin Kim
Gillian Gresham
Natalie Moshayedi
Jason Y. Ye
Julianne C. Yang
Jonathan P. Jacobs
Simon Lo
Nick Nissen
Srinivas Gaddam
Mourad Tighiouart
Arsen Osipov
Andrew Hendifar
机构：
[1] Samuel Oschin Comprehensive Cancer Institute,Department of Medicine
[2] Cedars-Sinai Medical Center,The Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine
[3] University of California,undefined
来源：
Scientific Reports | / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: A phase I and II trial
    Reni, M
    Panucci, MG
    Passoni, P
    Bonetto, E
    Nicoletti, R
    Ronzoni, M
    Zerbi, A
    Staudacher, C
    Di Carlo, V
    Villa, E
    CANCER INVESTIGATION, 2004, 22 (05) : 688 - 696
  • [42] 5-FLUOROURACIL AND FOLINIC ACID - A PHASE-I-II TRIAL IN GASTROINTESTINAL MALIGNANCY
    CUNNINGHAM, J
    BUKOWSKI, RM
    BUDD, GT
    WEICK, JK
    PURVIS, J
    INVESTIGATIONAL NEW DRUGS, 1984, 2 (04) : 391 - 395
  • [43] Phase I trial of gemcitabine (Gemzar®, 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer
    Oettle, H
    Pelzer, U
    Hochmuth, K
    Diebold, T
    Langrehr, J
    Schmidt, CA
    Arning, M
    Vogl, TJ
    Neuhaus, P
    Huhn, D
    Riess, H
    ANTI-CANCER DRUGS, 1999, 10 (08) : 699 - 704
  • [44] Phase I study of PTM-101 as neoadjuvant therapy for borderline resectable or locally advanced pancreatic ductal adenocarcinoma: A trial in progress.
    Pilgrim, Charles
    Smith, Marty
    Ban, Jun
    Ellis, Sam
    Zalcberg, John Raymond
    Markman, Ben
    Lashof-Sullivan, Margaret
    Indolfi, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS775 - TPS775
  • [45] A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
    C Garufi
    E Bria
    B Vanni
    A M R Zappalà
    I Sperduti
    E Terzoli
    British Journal of Cancer, 2003, 89 : 1870 - 1875
  • [46] Spontaneous Aortic Haematoma in a Patient Receiving Adjuvant Folinic Acid, 5-Fluorouracil, Irinotecan, and Oxaliplatin Chemotherapy Following Resection of a Pancreatic Adenocarcinoma
    Dacie, Ruth
    Woodhouse, Laura
    Mullan, Damian
    Lamarca, Angela
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (10)
  • [47] A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer
    Oettle, H
    Arning, M
    Pelzer, U
    Arnold, D
    Stroszczynski, C
    Langrehr, J
    Reitzig, P
    Kindler, M
    Herrenberger, J
    Musch, R
    Korsten, FW
    Huhn, D
    Riess, H
    ANNALS OF ONCOLOGY, 2000, 11 (10) : 1267 - 1272
  • [48] A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients
    Garufi, C
    Bria, E
    Vanni, B
    Zappalà, AMR
    Sperduti, I
    Terzoli, E
    BRITISH JOURNAL OF CANCER, 2003, 89 (10) : 1870 - 1875
  • [49] A Phase I Trial of Concurrent Immunotherapy and Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Adenocarcinoma
    Martin, R.
    Donaldson, M.
    Hayat, T.
    O'Neill, C.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S136 - S136
  • [50] A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
    Natalie Cook
    Bristi Basu
    Donna-Michelle Smith
    Aarthi Gopinathan
    Jeffry Evans
    William P Steward
    Daniel Palmer
    David Propper
    Balaji Venugopal
    Mirela Hategan
    D Alan Anthoney
    Lisa V Hampson
    Michael Nebozhyn
    David Tuveson
    Hayley Farmer-Hall
    Helen Turner
    Robert McLeod
    Sarah Halford
    Duncan Jodrell
    British Journal of Cancer, 2018, 118 : 793 - 801
12345